The Efficacy and Safety of Peginterferon-alpha-2a in Korean Patients with Chronic Hepatitis B: A Multicenter Study Conducted in a Real Clinical Setting
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kwon, Jung Hyun | - |
dc.contributor.author | Kim, Young Seok | - |
dc.contributor.author | Kim, Sang Gyune | - |
dc.contributor.author | Jang, Jeong Won | - |
dc.contributor.author | Kim, Tae Hun | - |
dc.contributor.author | Jung, Young Kul | - |
dc.contributor.author | Kwon, Oh Sang | - |
dc.date.accessioned | 2021-08-12T01:18:32Z | - |
dc.date.available | 2021-08-12T01:18:32Z | - |
dc.date.issued | 2013-03-15 | - |
dc.identifier.issn | 1976-2283 | - |
dc.identifier.issn | 2005-1212 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/sch/handle/2021.sw.sch/13825 | - |
dc.description.abstract | Background/Aims: Genotype C is the principal type of hepatitis B virus (HBV) in Koreans and is associated with poor prognosis for peginterferon alpha-2a therapy. The efficacy of and compliance to peginterferon a-2a therapy were investigated in Koreans with hepatitis B in a real clinical setting. Methods: Hepatitis B patients treated with peginterferon alpha-2a from 2008 to 2011 at four university hospitals were consecutively enrolled. Results: Eighty-eight patients were enrolled; 67 were hepatitis B e antigen (HBeAg)-positive. The mean treatment period was 36.1 +/- 15.2 weeks. In 26.1% of patients, treatment was discontinued due to insufficient antiviral effects and adverse events. At 24 weeks after treatment, 10/42 (23.8%) HBeAg-positive patients achieved both III3V DNA suppression to <2,000 IU/mL and HBeAg loss/seroconversion. For HBeAg-negative patients, 10/13 (76.9%) achieved HBV DNA suppression to <2,000 IU/niL at 24 weeks after treatment. During the follow-up period, 15 (30.6%) of the 49 patients who achieved HBV DNA suppression to 2,000 IU/mL developed a breakthrough HBV DNA level of >2x10(6) IU/mL. Conclusions: Peginterferon alpha-2a therapy in Koreans with hepatitis B in a real clinical setting resulted in a lower virologic response, as compared to Western individuals, but a favorable durability. There is a need to reduce the high rate of premature discontinuation compared to the controlled studies. (Gut Liver 2013;7:197-205) | - |
dc.format.extent | 9 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.publisher | 거트앤리버 발행위원회 | - |
dc.title | The Efficacy and Safety of Peginterferon-alpha-2a in Korean Patients with Chronic Hepatitis B: A Multicenter Study Conducted in a Real Clinical Setting | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.5009/gnl.2013.7.2.197 | - |
dc.identifier.scopusid | 2-s2.0-84875113234 | - |
dc.identifier.wosid | 000316304300010 | - |
dc.identifier.bibliographicCitation | Gut and Liver, v.7, no.2, pp 197 - 205 | - |
dc.citation.title | Gut and Liver | - |
dc.citation.volume | 7 | - |
dc.citation.number | 2 | - |
dc.citation.startPage | 197 | - |
dc.citation.endPage | 205 | - |
dc.type.docType | Article | - |
dc.identifier.kciid | ART001751839 | - |
dc.description.isOpenAccess | N | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.description.journalRegisteredClass | kciCandi | - |
dc.relation.journalResearchArea | Gastroenterology & Hepatology | - |
dc.relation.journalWebOfScienceCategory | Gastroenterology & Hepatology | - |
dc.subject.keywordPlus | PEGYLATED INTERFERON-ALPHA-2B | - |
dc.subject.keywordPlus | VIRUS GENOTYPES | - |
dc.subject.keywordPlus | COMBINATION | - |
dc.subject.keywordPlus | LAMIVUDINE | - |
dc.subject.keywordPlus | ALPHA-2A | - |
dc.subject.keywordPlus | TRIAL | - |
dc.subject.keywordAuthor | Peginterferon | - |
dc.subject.keywordAuthor | Chronic hepatitis B | - |
dc.subject.keywordAuthor | Asian continental ancestry group | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(31538) 22, Soonchunhyang-ro, Asan-si, Chungcheongnam-do, Republic of Korea+82-41-530-1114
COPYRIGHT 2021 by SOONCHUNHYANG UNIVERSITY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.